BLC
REGN icon

Brown, Lisle/Cummings’s Regeneron Pharmaceuticals REGN Stock Holding History

Brown, Lisle/Cummings’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.4K Buy
84
+2
+2% +$1.36K 0.01% 387
2026
Q1 		$63.4K Buy
82
+7
+9% +$5.36K 0.02% 321
2025
Q4 		$57.9K Hold
75
– – 0.01% 327
2025
Q3 		$42.2K Hold
75
– – 0.01% 359
2025
Q2 		$39.4K Hold
75
– – 0.01% 362
2025
Q1 		$47.6K Hold
75
– – 0.01% 334
2024
Q4 		$53.4K Buy
75
+10
+15% +$8.39K 0.02% 328
2024
Q3 		$68.3K Hold
65
– – 0.02% 292
2024
Q2 		$68.3K Buy
65
+10
+18% +$9.69K 0.02% 284
2024
Q1 		$52.9K Hold
55
– – 0.02% 287
2023
Q4 		$48.3K Hold
55
– – 0.02% 288
2023
Q3 		$45.3K Sell
55
-20
-27% -$15.7K 0.02% 278
2023
Q2 		$53.9K Hold
75
– – 0.02% 270
2023
Q1 		$61.6K Hold
75
– – 0.03% 260
2022
Q4 		$54.1K Hold
75
– – 0.03% 257
2022
Q3 		$51.7K Hold
75
– – 0.03% 249
2022
Q2 		$44.3K Hold
75
– – 0.02% 270
2022
Q1 		$52.4K Hold
75
– – 0.03% 262
2021
Q4 		$47.4K Buy
+75
New +$46.1K 0.02% 267

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Brown, Lisle/Cummings's REGN Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its Regeneron Pharmaceuticals (REGN) stake by 2.4% in Q2 2026, buying an estimated $1.36K and bringing the position to 84 shares worth $52.4K. The position accounts for 0.01% of the portfolio, ranked #387.

Brown, Lisle/Cummings first reported a position in REGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $68.3K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Brown, Lisle/Cummings held 84 shares of Regeneron Pharmaceuticals worth $52.4K as of Q2 2026.
  • Brown, Lisle/Cummings bought 2 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
  • Regeneron Pharmaceuticals made up 0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #387 holding.
  • Brown, Lisle/Cummings first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Brown, Lisle/Cummings's Regeneron Pharmaceuticals position peaked at $68.3K in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.